Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ICUNASDAQ:OBLNNASDAQ:PETVNASDAQ:PSTV On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeICUSeaStar Medical$0.43+5.1%$1.11$0.31▼$13.85$4.54M-0.891.50 million shs1.83 million shsOBLNObalon Therapeutics$2.44$4.22$0.66▼$10.77$24.45M-1.237.68 million shs136,689 shsPETVPetVivo$0.80+1.3%$0.71$0.29▼$0.98$19.17M0.8721,036 shs69,976 shsPSTVPlus Therapeutics$0.35+10.4%$0.44$0.16▼$2.31$16.07M0.649.91 million shs23.62 million shs2025 Gold Forecast: A Perfect Storm for DemandUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceICUSeaStar Medical+5.09%+28.26%-63.62%-71.62%-94.39%OBLNObalon Therapeutics0.00%-4.31%-50.31%+576.84%+1,173.49%PETVPetVivo+1.29%-0.01%+4.41%+35.65%+53.83%PSTVPlus Therapeutics+10.38%+88.71%+22.94%-65.90%-76.34%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationICUSeaStar Medical1.3778 of 5 stars0.05.00.00.03.11.70.0OBLNObalon TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/APETVPetVivoN/AN/AN/AN/AN/AN/AN/AN/APSTVPlus Therapeutics1.8792 of 5 stars3.32.00.00.02.90.00.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceICUSeaStar Medical 0.00N/AN/AN/AOBLNObalon Therapeutics 0.00N/AN/AN/APETVPetVivo 0.00N/AN/AN/APSTVPlus Therapeutics 2.50Moderate Buy$10.833,014.82% UpsideCurrent Analyst Ratings BreakdownLatest OBLN, PSTV, PETV, and ICU Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/27/2025PSTVPlus TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$5.50 ➝ $3.006/25/2025PSTVPlus TherapeuticsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingHold ➝ Hold$9.006/5/2025PSTVPlus TherapeuticsAscendiant Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$20.00 ➝ $20.505/5/2025PSTVPlus TherapeuticsD Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold5/5/2025PSTVPlus TherapeuticsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Hold4/21/2025PSTVPlus TherapeuticsAscendiant Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$19.00 ➝ $20.00(Data available from 7/1/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookICUSeaStar Medical$140K34.06N/AN/A($0.34) per share-1.25OBLNObalon Therapeutics$1.59M15.38N/AN/A$0.60 per share4.07PETVPetVivo$1.05M18.56N/AN/A($0.03) per share-26.66PSTVPlus TherapeuticsN/AN/AN/AN/A($1.52) per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateICUSeaStar Medical-$24.83M-$3.47N/A∞N/AN/AN/A-313.28%8/12/2025 (Estimated)OBLNObalon Therapeutics-$12.33MN/AN/A∞N/A-776.76%-161.38%-83.58%N/APETVPetVivo-$10.95M-$0.45N/A∞N/A-902.82%-4,813.07%-281.78%8/12/2025 (Estimated)PSTVPlus Therapeutics-$12.98M-$2.94N/AN/AN/A-520.90%N/A-202.73%8/13/2025 (Estimated)Latest OBLN, PSTV, PETV, and ICU EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/30/2025Q1 2025PSTVPlus Therapeutics-$0.17-$0.56-$0.39-$1.19$1.11 million$1.06 million5/14/2025Q1 2025ICUSeaStar Medical-$0.52-$0.44+$0.08-$0.44$0.15 million$0.29 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthICUSeaStar MedicalN/AN/AN/AN/AN/AOBLNObalon TherapeuticsN/AN/AN/AN/AN/APETVPetVivoN/AN/AN/AN/AN/APSTVPlus TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioICUSeaStar MedicalN/A0.960.96OBLNObalon TherapeuticsN/A1.861.86PETVPetVivo0.020.420.47PSTVPlus TherapeuticsN/A1.031.03Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipICUSeaStar Medical1.69%OBLNObalon Therapeutics18.64%PETVPetVivo24.55%PSTVPlus Therapeutics3.28%Insider OwnershipCompanyInsider OwnershipICUSeaStar Medical1.30%OBLNObalon Therapeutics8.10%PETVPetVivo10.84%PSTVPlus Therapeutics3.76%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableICUSeaStar Medical211.20 million11.06 millionNot OptionableOBLNObalon Therapeutics210.02 millionN/ANot OptionablePETVPetVivo2024.27 million19.06 millionNot OptionablePSTVPlus Therapeutics2051.00 million48.20 millionNot OptionableOBLN, PSTV, PETV, and ICU HeadlinesRecent News About These CompaniesPlus Therapeutics Announces FDA Agreement to Initiate ReSPECT-LM Dose Optimization Trial for REYOBIQ™ in Leptomeningeal MetastasesJune 30 at 7:30 AM | globenewswire.comPlus Therapeutics (NASDAQ:PSTV) Price Target Cut to $3.00 by Analysts at HC WainwrightJune 28 at 2:24 AM | americanbankingnews.comD. Boral Capital Reiterates Hold Rating for Plus Therapeutics (NASDAQ:PSTV)June 27, 2025 | americanbankingnews.comPlus Therapeutics Provides Business Update on CNSide Diagnostics SubsidiaryJune 26, 2025 | globenewswire.comPlus Therapeutics to Provide Business Update and Host Conference Call on Thursday, June 26, 2025 at 9:00 A.M. ETJune 25, 2025 | globenewswire.comPlus Therapeutics Announces FDA Clearance of its Investigational New Drug Application using REYOBIQTM for the Treatment of Childhood Brain CancerJune 25, 2025 | globenewswire.comPlus Therapeutics Restructures Financing to Eliminate Potential Dilution of 1.5 Billion SharesJune 24, 2025 | quiverquant.comQPlus Therapeutics Announces Comprehensive Restructuring of $15 Million March 2025 Equity FinancingJune 24, 2025 | globenewswire.comPlus (PSTV) Upgraded to Buy: Here's WhyJune 19, 2025 | zacks.comPlus Therapeutics Modifies Security Holders’ RightsJune 17, 2025 | tipranks.comPlus Therapeutics Reports First Quarter Financial Results and Recent Business HighlightsMay 30, 2025 | finance.yahoo.comPlus Therapeutics (PSTV) Reports Q1 Loss, Misses Revenue EstimatesMay 30, 2025 | zacks.comPlus Therapeutics, Inc. Reports Q1 2025 Financial Results and Updates on REYOBIQ™ Trials and CNSide® Assay Platform ProgressMay 30, 2025 | quiverquant.comQPlus Therapeutics Reports First Quarter Financial Results and Recent Business HighlightsMay 30, 2025 | globenewswire.comPlus Therapeutics, Inc. Receives Notification of Deficiency from Nasdaq Related to Delayed ...May 23, 2025 | gurufocus.comPlus Therapeutics, Inc. Receives Notification of Deficiency from Nasdaq Related to Delayed Filing of Quarterly Report on Form 10-QMay 23, 2025 | globenewswire.comPlus Therapeutics reports progress in CNS cancer therapyMay 15, 2025 | investing.comPlus Therapeutics’ REYOBIQ™ Shows Clinical Benefit and Safety in the ReSPECT-LM Clinical Trial for Patients with Leptomeningeal Metastases (LM)May 15, 2025 | finance.yahoo.comPlus Therapeutics (PSTV) May Report Negative Earnings: Know the Trend Ahead of Q1 ReleaseMay 14, 2025 | zacks.comPlus Therapeutics' REYOBIQ™ Shows Clinical Benefit and Safety in the ReSPECT-LM Clinical Trial for Patients with Leptomeningeal Metastases (LM)May 14, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeOBLN, PSTV, PETV, and ICU Company DescriptionsSeaStar Medical NASDAQ:ICU$0.43 +0.02 (+5.09%) Closing price 06/30/2025 04:00 PM EasternExtended Trading$0.42 0.00 (-1.10%) As of 09:15 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.SeaStar Medical Holding Corporation, a medical device company, develops a platform therapy to reduce the consequences of hyperinflammation on vital organs in the United States. The company offers inflammatory response to fend off infections and repair damaged tissue in the body. It is also developing products in various therapeutic areas, including pediatric and adult acute kidney injury on CRRT; cardiorenal syndrome in congestive heart failure; myocardial stunning in end stage renal disease; and hepatorenal syndrome. The company is headquartered in Denver, Colorado.Obalon Therapeutics NASDAQ:OBLNObalon Therapeutics, Inc., a vertically integrated medical device company, focuses on developing and commercializing medical devices to treat people with obesity. The company offers the Obalon Balloon System designed to provide weight loss in patients with obesity. Its Obalon Balloon System comprises of a swallowable capsule that contains an inflatable balloon attached to a microcatheter; the Obalon Navigation System console, which is a combination of hardware and software used to track and display the location of the balloon during placement; the Obalon Touch Inflation Dispenser, which is a semi-automated, hand-held inflation device used to inflate the balloon once it is placed; and a disposable canister filled with mixture of gas. Obalon Therapeutics, Inc. was incorporated in 2008 and is headquartered in Carlsbad, California.PetVivo NASDAQ:PETV$0.80 +0.01 (+1.29%) As of 06/30/2025 03:47 PM EasternPetVivo Holdings, Inc., a biomedical device company, engages in the manufacturing, commercializing, and licensing of medical devices and biomaterials for the treatment of afflictions and diseases in animals. Its lead product is Spryng, a veterinarian-administered, intraarticular injection for the management of lameness and other joint afflictions, such as osteoarthritis in dogs and horses. The company's pipeline products also include therapeutic devices for veterinary and human clinical applications. PetVivo Holdings, Inc. was founded in 2009 and is headquartered in Minneapolis, Minnesota.Plus Therapeutics NASDAQ:PSTV$0.35 +0.03 (+10.38%) Closing price 06/30/2025 04:00 PM EasternExtended Trading$0.33 -0.02 (-4.83%) As of 09:18 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. Its lead radiotherapeutic drug candidate is rhenium (186Re) obisbemeda, a patented radiotherapy that targets central nervous system cancers and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. The company also develops Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere that is designed to treat various solid organ cancers comprising primary and secondary liver cancers by intra-arterial injection. It has license agreements with NanoTx, Corp. and The University of Texas Health Science Center at San Antonio. The company was formerly known as Cytori Therapeutics, Inc. and changed its name to Plus Therapeutics, Inc. in July 2019. Plus Therapeutics, Inc. was founded in 1996 and is headquartered in Austin, Texas. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Palantir’s $100M Nuclear OS Pact Boosts Bullish Case Joby Stock Soars as Piloted Flights in Dubai Signal a New Era Tesla’s Robotaxi Hype Fuels Bullish Price Targets to $500 S&P 500 All-Time Highs: 5 Catalysts Driving It Higher The Top Insider Sells From Q2: Buy, Sell, or Hold? 5 High-Yielding ETFs to Buy and Hold Forever Why BigBear.ai Could Rally 100% and Catch Palantir Soon Why McCormick Stock Could Soar After Durables Data Surprise Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
